Atossa Therapeutics (ATOS) News Today $0.80 -0.04 (-5.32%) Closing price 02/21/2025 04:00 PM EasternExtended Trading$0.81 +0.02 (+2.11%) As of 02/21/2025 07:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period Atossa Therapeutics, Inc. (NASDAQ:ATOS) Sees Significant Growth in Short InterestAtossa Therapeutics, Inc. (NASDAQ:ATOS - Get Free Report) was the recipient of a large increase in short interest in January. As of January 31st, there was short interest totalling 9,250,000 shares, an increase of 5.8% from the January 15th total of 8,740,000 shares. Based on an average daily volume of 876,500 shares, the days-to-cover ratio is presently 10.6 days.February 17, 2025 | marketbeat.comAtossa Therapeutics (NASDAQ:ATOS) Stock Crosses Below 200 Day Moving Average - Here's WhyAtossa Therapeutics (NASDAQ:ATOS) Shares Pass Below 200-Day Moving Average - Here's WhyFebruary 11, 2025 | marketbeat.comAtossa Therapeutics Congratulates Board Director Dr. Tessa Cigler and Weill Cornell Medicine on CDC Grant to Enhance Breast Cancer CareFebruary 5, 2025 | globenewswire.comWhat is HC Wainwright's Estimate for ATOS FY2029 Earnings?Atossa Therapeutics, Inc. (NASDAQ:ATOS - Free Report) - Investment analysts at HC Wainwright issued their FY2029 earnings estimates for shares of Atossa Therapeutics in a research report issued to clients and investors on Thursday, January 30th. HC Wainwright analyst E. Bodnar expects that the coFebruary 4, 2025 | marketbeat.comEquities Analysts Set Expectations for ATOS FY2029 EarningsAtossa Therapeutics, Inc. (NASDAQ:ATOS - Free Report) - Equities research analysts at HC Wainwright issued their FY2029 EPS estimates for Atossa Therapeutics in a report released on Thursday, January 30th. HC Wainwright analyst E. Bodnar anticipates that the company will earn ($0.14) per share foFebruary 3, 2025 | marketbeat.comAtossa Genetics stock hits 52-week low at $0.75January 30, 2025 | msn.comAtossa Therapeutics: Strong Strategic Positioning and Patent Resilience Justifies Buy RatingJanuary 30, 2025 | markets.businessinsider.comHC Wainwright Reiterates "Buy" Rating for Atossa Therapeutics (NASDAQ:ATOS)HC Wainwright reaffirmed a "buy" rating and set a $7.00 price target on shares of Atossa Therapeutics in a research report on Thursday.January 30, 2025 | marketbeat.comAtossa Therapeutics Responds to PTAB Ruling on U.S. Patent No. 11,572,334 and Announces the Issuance of U.S. Patent No. 12,201,591January 30, 2025 | finance.yahoo.comAtossa Therapeutics faces patent setback, continues developmentJanuary 30, 2025 | msn.comAtossa Therapeutics Responds to PTAB Ruling on U.S. Patent No. 11,572,334 and Announces the Issuance of U.S. Patent No.January 30, 2025 | globenewswire.comAtossa Therapeutics reports progress in breast cancer treatmentsJanuary 23, 2025 | msn.comAtossa Therapeutics Issues Letter to Shareholders Highlighting 2024 Accomplishments and Outlook for 2025January 23, 2025 | globenewswire.comSeattle Doctor: Quit Drinking NowJanuary 7, 2025 | msn.comAtossa Therapeutics ‘applauds’ Surgeon General’s advisory on alcoholJanuary 7, 2025 | markets.businessinsider.comAtossa Therapeutics Applauds U.S. Surgeon General’s Advisory Highlighting Alcohol as a Leading Preventable Cause of Breast CancerJanuary 6, 2025 | markets.businessinsider.comCapricor Therapeutics: Promising Advances in Duchenne Cardiomyopathy Treatment Drive Buy RatingJanuary 4, 2025 | markets.businessinsider.comAtossa Therapeutics, Inc. (NASDAQ:ATOS) Sees Large Decrease in Short InterestAtossa Therapeutics, Inc. (NASDAQ:ATOS - Get Free Report) was the recipient of a significant drop in short interest during the month of December. As of December 15th, there was short interest totalling 8,200,000 shares, a drop of 29.3% from the November 30th total of 11,600,000 shares. Based on an average daily volume of 705,500 shares, the short-interest ratio is currently 11.6 days.December 28, 2024 | marketbeat.comAtossa Therapeutics, Inc. (NASDAQ:ATOS) Short Interest Down 6.8% in NovemberAtossa Therapeutics, Inc. (NASDAQ:ATOS - Get Free Report) saw a large decline in short interest in the month of November. As of November 30th, there was short interest totalling 11,600,000 shares, a decline of 6.8% from the November 15th total of 12,450,000 shares. Based on an average daily volume of 628,500 shares, the days-to-cover ratio is presently 18.5 days.December 16, 2024 | marketbeat.comAtossa Therapeutics: Promising Clinical Results Reinforce Buy Rating with Z-endoxifen AdvancementsDecember 12, 2024 | markets.businessinsider.comAtossa Therapeutics to Present Poster Describing the Discovery of Molecules Synergistic with (Z)-endoxifen for the Treatment of Breast Cancer at the 2024 San Antonio Breast Cancer SymposiumDecember 12, 2024 | globenewswire.comAtossa Therapeutics’ Promising EVANGELINE Study and Strong Buy Rating from Analyst Jason McCarthyDecember 11, 2024 | markets.businessinsider.comAtossa Therapeutics announces resuts from Phase 2 KARISMA-Endoxifen studyDecember 11, 2024 | markets.businessinsider.comAtossa's 1 MG Z-Endoxifen Shows Reduction In Dense Breast Tissue In Premenopausal WomenDecember 11, 2024 | markets.businessinsider.comAtossa Therapeutics Announces Full Results from Phase 2 KARISMA-Endoxifen Study Demonstrating Statistically Significant Reductions in Mammographic Breast DensityDecember 11, 2024 | globenewswire.comAtossa Therapeutics announces three posters on Phase 2 EVANGELINE trialDecember 10, 2024 | markets.businessinsider.comAtossa Therapeutics to Present Pharmacokinetic and Tolerability Data from Phase 2 EVANGELINE Trial at the 2024 San Antonio Breast Cancer SymposiumDecember 10, 2024 | globenewswire.comAscendiant Capital Markets Forecasts Strong Price Appreciation for Atossa Therapeutics (NASDAQ:ATOS) StockAscendiant Capital Markets lifted their target price on shares of Atossa Therapeutics from $6.50 to $7.00 and gave the company a "buy" rating in a research report on Monday.December 9, 2024 | marketbeat.comAtossa Therapeutics Presents Data from Study Investigating Anti-Cancer Activity of (Z)-Endoxifen-Related Compounds at AACR Special Conference in Cancer ResearchDecember 9, 2024 | globenewswire.comAtossa Therapeutics to Present Poster on (Z)-Endoxifen at AACR Special Conference in Cancer ResearchNovember 21, 2024 | globenewswire.comAtossa Therapeutics announces five abstracts on Z-endoxifenNovember 21, 2024 | markets.businessinsider.comAtossa Therapeutics Announces Five Abstracts Highlighting (Z)-Endoxifen Research Accepted for Presentation at the 2024 San Antonio Breast Cancer SymposiumNovember 20, 2024 | globenewswire.comFY2024 EPS Estimates for ATOS Boosted by Cantor FitzgeraldAtossa Therapeutics, Inc. (NASDAQ:ATOS - Free Report) - Equities researchers at Cantor Fitzgerald increased their FY2024 earnings per share (EPS) estimates for shares of Atossa Therapeutics in a research note issued to investors on Wednesday, November 13th. Cantor Fitzgerald analyst L. Chen now aNovember 18, 2024 | marketbeat.comEquities Analysts Offer Predictions for ATOS FY2026 EarningsAtossa Therapeutics, Inc. (NASDAQ:ATOS - Free Report) - HC Wainwright decreased their FY2026 EPS estimates for Atossa Therapeutics in a report issued on Wednesday, November 13th. HC Wainwright analyst E. Bodnar now anticipates that the company will post earnings per share of ($0.32) for the year,November 15, 2024 | marketbeat.comAtossa Therapeutics: Promising Oncology Asset and Strong Financial Position Justify Buy RatingNovember 14, 2024 | markets.businessinsider.comAtossa Therapeutics, Inc.: Atossa Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate UpdateNovember 13, 2024 | finanznachrichten.deAtossa Therapeutics: Q3 2024 Financial Results and UpdatesNovember 13, 2024 | markets.businessinsider.comPromising Developments in Atossa Therapeutics: Advancing Endoxifen TreatmentsNovember 13, 2024 | markets.businessinsider.comAtossa Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate UpdateNovember 12, 2024 | globenewswire.comAtossa Therapeutics (NASDAQ:ATOS) Downgraded to "Sell" Rating by StockNews.comStockNews.com cut shares of Atossa Therapeutics from a "hold" rating to a "sell" rating in a report on Friday.November 8, 2024 | marketbeat.comAtossa Therapeutics: Important News, But The Company Still Has A Long Way To GoNovember 8, 2024 | seekingalpha.comAtossa Therapeutics (NASDAQ:ATOS) Stock Crosses Above 200 Day Moving Average - Should You Sell?Atossa Therapeutics (NASDAQ:ATOS) Stock Price Passes Above Two Hundred Day Moving Average - Here's WhyNovember 8, 2024 | marketbeat.comPositive Phase 2 Results and Rapid Efficacy Drive Buy Rating for Atossa TherapeuticsNovember 6, 2024 | markets.businessinsider.comAtossa Therapeutics appoints Claudia Lopez as VP, clinical developmentNovember 5, 2024 | markets.businessinsider.comAtossa Therapeutics Appoints Claudia Lopez, DVM, MSc, as Vice President, Clinical Product DevelopmentNovember 5, 2024 | globenewswire.comHR+ HER2-ve Breast Cancer Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and BarriersNovember 5, 2024 | theglobeandmail.comAtossa repots topline data from the KARISMA-Endoxifen Phase 2 studyNovember 4, 2024 | markets.businessinsider.comPromising Phase 2 Results and Strong Safety Profile Support Buy Recommendation for Atossa TherapeuticsNovember 4, 2024 | markets.businessinsider.comAtossa Therapeutics Reports Positive KARISMA-Endoxifen Trial Results:November 4, 2024 | globenewswire.comBuy Rating for Atossa Therapeutics Backed by Promising Endoxifen Trial Results and Rapid Therapeutic AchievementsNovember 2, 2024 | markets.businessinsider.com Get Atossa Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ATOS and its competitors with MarketBeat's FREE daily newsletter. Email Address ATOS Media Mentions By Week ATOS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ATOS News Sentiment▼1.940.60▲Average Medical News Sentiment ATOS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ATOS Articles This Week▼12▲ATOS Articles Average Week Get Atossa Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ATOS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies GLUE News UPB News ATXS News AURA News PHAT News CMRX News ORKA News ATAI News RVNC News PRME News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ATOS) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | Sponsored[RFK Jr CONFIRMED] Here’s why Dems are TERRIFIEDRobert F. Kennedy Jr was just confirmed as Trump’s secretary of Health and Human Services… but it was NOT easy...NewMarket Health Publishing, LLC. | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementGrab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which ...Crypto 101 Media | SponsoredWhy Buffett and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this win...Behind the Markets | SponsoredMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now...Colonial Metals | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Atossa Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Atossa Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
